Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy
Study Details
Study Description
Brief Summary
This trial is a combination of trastuzumab and pyrotinib in the treatment of patients with HER2-positive metastatic breast cancer who have progressed on TKI therapy. A total of 50 patients were enrolled in the study design. Preliminary efficacy and safety in patients with HER2-positive metastatic breast cancer who have progressed on TKI therapy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Trastuzumab Emtansine for Injection；Pyrotinib Maleate Tablets Trastuzumab Emtansine for Injection: 3.6 mg/kg body weight (IV), administered on day 1, 21 days as a treatment cycle; Pyrotinib Maleate Tablets: The initial dose is 320 mg (PO), administered orally within 30 minutes after meals, at the same time every day, 21 days as a treatment cycle; Efficacy was assessed every two cycles and treatment was continued until disease progression or intolerable toxicity or death. |
Drug: Trastuzumab Emtansine for Injection
3.6 mg/kg body weight (IV), administered on day 1, 21 days as a treatment cycle;
Drug: Pyrotinib Maleate Tablets
The initial dose is 320 mg (PO), administered orally within 30 minutes after meals, at the same time every day, 21 days as a treatment cycle;
|
Outcome Measures
Primary Outcome Measures
- ORR(objective response rate) [Estimated 24 months]
rate of CR and PR in all subjects
Eligibility Criteria
Criteria
Inclusion criteria：
-
Female breast cancer patients aged ≥18 years and ≤75 years old
-
HER2 positive (IHC3+, or IHC2+ and positive FISH test) confirmed by the center
-
ECOG score 0-1
-
Patients with advanced breast cancer who have progressed on lapatinib or pyrotinib
-
There are measurable lesions
-
Left ventricular ejection fraction (LVEF) ≥ 50%
-
12-lead ECG: Fridericia-corrected QT interval (QTcF) in women < 470 ms;
-
The function level of major organs must meet the following requirements: blood routine: ANC≥1.5×109/L; PLT≥90×109/L; Hb≥90g/L; blood biochemistry: TBIL≤2.5×ULN; ALT and AST≤2.5 ×ULN; BUN and Cr ≤ 1.5×ULN;
-
For female subjects who are not menopausal or surgically sterilized, agree to abstain from sex or use effective contraceptive methods during the treatment period and for at least 2 months after the last dose in the study treatment;
-
Voluntarily join the study, sign informed consent, have good compliance and be willing to cooperate with follow-up.
exclusion criteria：
-
Patients who have previously used ADCs to treat advanced breast cancer
-
Symptomatic patients with brain metastases
-
Control unstable pleural effusion and ascites patients
-
Patients with previous or concurrent malignancies whose natural medical history or treatment may interfere with the safety or efficacy assessment of the study protocol are not eligible to participate in this trial, except for basal cell or squamous cell skin cancer, cervical cancer in situ, or bladder cancer , or the subject has lived free of disease (other cancers) for at least 5 years.
-
Active infection requiring systemic treatment
-
Gastrointestinal dysfunction or disease that may seriously affect the absorption of the study drug (such as ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection) or severely impair the ability to swallow capsules/tablets
-
Known history of myelodysplastic syndrome or acute myeloid leukemia
-
History of abdominal fistula, gastrointestinal perforation or abdominal abscess within 28 days
-
Any history of cerebrovascular accident (CVA) or transient ischemic attack within 12 months
-
History of acute coronary syndrome (including myocardial infarction, unstable angina, coronary artery, arterial bypass grafting, coronary angioplasty or stenting) or symptomatic pericarditis within 6 years
-
Symptomatic congestive heart failure (New York Heart Association III-IV) or cardiomyopathy with left ventricular ejection fraction (LVEF) <50%
-
Clinically significant ventricular arrhythmia (sustained tachycardia/ventricular fibrillation) or high-grade AV block (eg, bifascicular block, Mobitz type II, and third-degree AV block), unless fitted pacemaker
-
Any concurrent severe and/or uncontrolled medical conditions that, in the judgment of the investigator, would result in unacceptable safety risks, prohibit subjects from participating in clinical studies, or affect protocol compliance
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Tianjin Medical University Cancer Institute and Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- BC- T-DM1